Invivoscribeは、中国でリューコストラットCDx FLT3変異検査®を国家食品薬品監督管理総局（NMPA）に提出し、事業を拡大、また上海に検査室を追加してパートナーに総合的なサポートを提供。marketing2021-12-29T16:44:19+00:00May 12th, 2020|2020 プレスリリース, プレスリリース| 続きを読む
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatmentmarketing2021-02-15T19:48:14+00:00May 6th, 2020|2020 Publications, Publications| 続きを読む
Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myelomamarketing2021-02-11T21:50:38+00:00May 1st, 2020|2020 Publications, Publications| 続きを読む
Primary non-Hodgkin lymphoma of the tongue base: the clinicopathology of seven cases and evaluation of HPV and EBV statusmarketing2021-02-11T21:53:32+00:00April 1st, 2020|2020 Publications, Publications| 続きを読む
Quantitation of CMV Specific T-Cell Expansion Using T Cell Receptor Beta Locus Deep Sequencing to Identify Patients at Risk of Viral Complicationsmarketing2021-02-11T21:56:18+00:00March 1st, 2020|2020 Publications, Publications| 続きを読む
Clinical Utility of NGS in Lymphoid Malignanciesmarketing2021-02-23T01:10:44+00:00February 27th, 2020|2020 Videos, Videos, Webinars| 続きを読む
Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patientsmarketing2021-02-11T21:58:45+00:00February 6th, 2020|2020 Publications, Publications| 続きを読む
Monitoring minimal residual disease in the bone marrow using next generation sequencingmarketing2021-02-11T22:00:56+00:00January 17th, 2020|2020 Publications, Publications| 続きを読む
欧州委員会、InvivoscribeのリューコストラットCDx FLT3変異検査®などの有効性を確認済みの検査で検出されたFLT3変異を有する再発性または難治性の急性骨髄性白血病患者用にアステラス製薬のXOSPATA®を承認marketing2021-12-29T16:44:55+00:00December 5th, 2019|2019 プレスリリース, プレスリリース| 続きを読む
Plasma Cell Myeloma Residual Disease Quantitation Using a Next-Generation Sequencing-Based IGH Clonal Rearrangement Assay with the Aid of a “Spike-in” Clonal Sequencemarketing2021-02-11T23:36:10+00:00November 13th, 2019|2019 Publications, Publications| 続きを読む
